The Indian Pharma Market (IPM) achieved significant growth of 17.2 per cent during April 2015 and attained a sales of Rs. 8,047 crore. According to AIOCD AWACS report, Cipla grew by 25.1 per cent followed by Macleods at 18.9 per cent and Sun Pharmaceuticals at 18.4 per cent during April 2015. Among the 50 companies, 26 companies have crossed the IPM growth of 17.2 percent.

The IPM achieved highest growth of 17.2 per cent and reached at Rs. 21,968 crore during January March 2015, after two and half years.

Indian companies have grown at 17.1 per cent versus 17.5 per cent for MNCs in April 2015. Amongst the top 50 companies in MNCs, Allergan grew by 35.5 per cent followed by MSD at 34.9 per cent and Merck at 30.6 per cent. Under the non-NLEM category Indian companies grew at 18.3 per cent whereas MNCs grew at 18.8 per cent.  

The pharma players launched 162 brands and 300 SKUs in April 2015 and Sovihep, Eliquis and Revital-H brands remained on top. Glycomet – GP became the no 1 brand for April 2015 with a value of Rs. 29.53 crore and growth of 18.6 per cent with a MAT value of Rs. 299 crore. Among the top ten brands, Lantus grew at 37.3 per cent, Monocef at 36.6 per cent, Glycomet-GP at 33.3 per cent, Dexorange at 34.7 per cent, Augmentin at 29.7 per cent and Becosules at 29.1 per cent.

The Indian pharmaceutical market of paracetamol grew at 18.9 per cent, atorvastatin 12.7 per cent, probiotic microbes at 12.2 per cent, cefixime 19.2 per cent, pantnoprazole 22.7 per cent. Further, Montelukast plus levocetrizine grew by 25.3 per cent, glimepiride plus metformin plu pioglitazone at 19.6 per cent, vitamin-D at 35.9 per cent. From regional perspective 14 regions have outgrown the IPM growth. North AP market grew the highest at 31.1 per cent followed by Jharkhand market at 27.8 per cent and South AP market at 25.2 per cent.  

The total size of IPM improved by 14.1 per cent to Rs. 88,111 crore during Mar-April 2015 from Rs. 77,234 crore in the same period of last year ended April 2014. Top ten companies registered growth of 13.9 per cent to Rs. 38,895 crore followed by top 11-25 companies 15.2 per cent to Rs. 24,755 crore and 26-50 companies 14.9 per cent to Rs. 11,793 crore.  

AIOCD Pharmasofttech AWACS Pvt. Ltd. is a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors Ltd. (AIOCD Ltd) in a joint venture with Trikaal Mediinfotech Pvt. Ltd.

AIOCD AWACS is a pharmaceutical market research organisation that has evolved into an IT infrastructure player in pharma distribution & retail.